Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

E.D. Kwon, C.G. Drake, H.I. Scher, K. Fizazi, A. Bossi, A.J.M. van den Eertwegh, M. Krainer, N. Houede, R. Santos, H. Mahammedi, S. Ng, M. Di Maio, F.A. Franke, S. Sundar, N. Agarwal, A.M. Bergman, T.E. Ciuleanu, E. Korbenfeld, L. Sengelov, S. HansenC. Logothetis, T.M. Beer, M.B. McHenry, P. Gagnier, D. Liu, W. Gerritsen

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)700-712
JournalLancet Oncology
Issue number7
Publication statusPublished - 2014

Cite this